Kexing Pharmaceutical Secures Rights for Chia Tai Tianqing’s Generic Ibrance in 11 Countries
Kexing Pharmaceutical (SHA: 688136), based in China, has entered into an international collaboration agreement with...
SHA: 688136
Kexing Pharmaceutical Partners with Yabao to Distribute Generic Nexavar in Ten Countries
China-based Kexing Pharmaceutical (SHA: 688136) has entered into an overseas cooperation agreement with fellow domestic...
Kexing Pharmaceutical Enters Global Licensing Agreement with Xiling Lab for Eribulin Generic
China-based Kexing Pharmaceutical (SHA: 688136) has entered into a global licensing and supply agreement with...
Convalife Pharmaceuticals Gets NMPA Approval for Generic Neratinib Clinical Study
Shanghai-based Convalife Pharmaceuticals has announced that it has received approval from the National Medical Products...
Kexing Pharmaceutical Secures Commercial Rights for Convalife’s Neratinib Generic Outside China
China-based Kexing Pharmaceutical (SHA: 688136) has announced a licensing agreement with compatriot firm Convalife, securing...
Kexing Pharmaceutical Initiates Phase I Trial for IFN-Alpha-1b Inhalation Solution
China-based Kexing Pharmaceutical (SHA: 688136) has announced the enrollment of the first subject and dosing...
Tonghua Dongbao Licenses Biosimilar Victoza to Kexing for Emerging Markets
China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) announced a licensing agreement with compatriot firm Kexing Pharmaceutical...
Kexing Pharma Receives Ethical Approval for Phase II Study of SHEN26 COVID-19 Drug
China-based Kexing Pharmaceutical (SHA: 688136) has announced receiving ethical approval to conduct a Phase II...
Kexing Pharmaceutical Launches Phase III Influenza Vaccine Study in Chile
China-based Kexing Pharmaceutical (SHA: 688136) announced the start of a Phase III clinical trial in...
Kexing Pharmaceutical’s SHEN26 COVID-19 Drug Receives NMPA Approval for Clinical Trials
China-based Kexing Pharmaceutical (SHA: 688136) announced that its oral small-molecule COVID-19 drug SHEN26, co-developed with...
Kexing Pharmaceutical’s Oral COVID-19 Drug SHEN26 Accepted for Clinical Trial Review
China-based Kexing Pharmaceutical (SHA: 688136) announced that a clinical trial application for SHEN26, an oral...